Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?
We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...
Biogen Holds On, But Growth Slips Through Its Fingers
Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.
BioSpace2dOpinion
Opinion: The Cocktail Recipe That Will Cure Alzheimer’s
Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...
Irish Examiner on MSN10h
Breakthrough drugs herald ‘new era’ in battle against dementia, experts predict
Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...
Pharmaceutical Technology9d
Felzartamab by Biogen for Lupus Nephritis: Likelihood of Approval
Felzartamab is under clinical development by Biogen and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate ...